Photosensitizer

Pulsed lighting for Corneal Atrophy

Phase 1 & 2

Waitlist Available

Led By Vishal Jhanji, MD

Research Sponsored by Vishal Jhanji

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Predicted Post LASIK/PRK stromal ablation depth <350 microns or expected keratometry >47.2 D, or patients undergoing PRK/SMILE in keratoconus suspect eye

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up12 months

Awards & highlights

No Placebo-Only Group

Study Summary

This trial is testing a new way to treat corneal thinning disorders using UV light and a photosensitizer called riboflavin.

Eligible Conditions

Corneal Atrophy
Keratoconus

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

Your cornea is too thin or misshaped for LASIK or PRK surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PXL-Platinum 330 system

Other outcome measures

Efficacy measurements by best spectacle-corrected visual acuity

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Pulsed lightingExperimental Treatment1 Intervention

Group II: Continuous lightingExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a site

Who is running the clinical trial?

Vishal JhanjiLead Sponsor

1 Previous Clinical Trials

50 Total Patients Enrolled

Vishal Jhanji, MDPrincipal Investigator

UPMC Eye Center

1 Previous Clinical Trials

50 Total Patients Enrolled

Media Library

Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) Clinical Trial Eligibility Overview. Trial Name: NCT05489510 — Phase 1 & 2

Corneal Atrophy Research Study Groups: Pulsed lighting, Continuous lighting

Corneal Atrophy Clinical Trial 2023: Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution Highlights & Side Effects. Trial Name: NCT05489510 — Phase 1 & 2

Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489510 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still enrolling patients in this clinical trial?

"The clinical trial in question is no longer recruiting patients. The study was first posted on 1/15/2023 and the last update to the posting was 11/10/2022. Although this particular research project has completed subject recruitment, there are 54 other studies which are still actively looking for participants."

Answered by AI